Brought to you by 
Grifols to buy Talecris for $3.4bn
05 May 2011
Executive Summary
Plasma protein manufacturer Grifols SA will buy publicly traded Talecris Biotherapeutics Inc. (coagulation, immunology, critical care, neurology, and pulmonary treatments) in a deal valued at $3.4bn, plus $600mm in debt. Grifols is paying $19 in cash and issuing 0.641 new non-voting shares for each outstanding Talecris share. The implied price comes out to $26.16 per share (a 59% premium).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com